Simvastatin Tablet, Film Coated
Product Images NDC 70518-3349

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Simvastatin (NDC 70518-3349). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
SIMVASTATIN 40 mg film-coated tablet label showing a quantity of 30 tablets. The label includes the NDC number 70518-3349-00 and states the medication is repackaged by RemedyRepack Inc. It indicates storage instructions and cautions to keep medication out of reach of children. Manufactured by Lupin Ltd., Goa, India.*
FDA Label Image

Mm2 (Simvastatin 40mg 70518 3349 01)

Mm2 (Simvastatin 40mg 70518 3349 01)
Simvastatin 40 mg film-coated tablet label showing a single tablet quantity. The label includes the NDC 70518-3349-01, mentions repackaging by RemedyRepack Inc., and indicates the manufacturer as Lupin Ltd, Goa, India. It contains storage instructions and a warning to keep the medication out of reach of children.*
FDA Label Image

Fig01 (Ae7ee793 92ec 44e2 85d2 33a672edd54e 01)

Fig01 (Ae7ee793 92ec 44e2 85d2 33a672edd54e 01)
Chemical structure of simvastatin, showing its molecular arrangement with multiple rings, hydroxyl groups, and methyl substituents as depicted in the image.*
FDA Label Image

Fig1 (Ae7ee793 92ec 44e2 85d2 33a672edd54e 02)

Fig1 (Ae7ee793 92ec 44e2 85d2 33a672edd54e 02)
A figure showing the effects of simvastatin treatment on major vascular events and major coronary events in different patient subgroups. The chart compares incidence percentages between simvastatin and placebo groups across various baseline characteristics, displaying risk ratios with 95% confidence intervals favoring either simvastatin or placebo. Baseline characteristics include diabetes status, peripheral vascular disease, cerebrovascular disease, gender, age, LDL-cholesterol, and HDL-cholesterol levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.